Literature DB >> 22406925

Soluble factors secreted by glioblastoma cell lines facilitate recruitment, survival, and expansion of regulatory T cells: implications for immunotherapy.

Courtney A Crane1, Brian J Ahn, Seunggu J Han, Andrew T Parsa.   

Abstract

In patients with glioma, the tumor microenvironment can significantly impact pro-inflammatory immune cell functions. However, the mechanisms by which this occurs are poorly defined. Because immunosuppressive regulatory T cells (Treg) are over represented in the tumor microenvironment compared with peripheral blood, we hypothesized that the tumor may have an effect on Treg survival, migration, expansion, and/or induction of a regulatory phenotype from non-Treg conventional CD4+ T cells. We defined the impact of soluble factors produced by tumor cells on Treg from healthy patients in vitro to determine mechanisms by which gliomas influence T cell populations. We found that tumor-derived soluble factors allowed for preferential proliferation and increased chemotaxis of Treg, compared with conventional T cells, indicating that these mechanisms may contribute to the increased Treg in the tumor microenvironment. Conventional T cells also exhibited a significantly increased expression of pro-apoptotic transcripts in the presence of tumor-derived factors, indicating that survival of Treg in the tumor site is driven by exposure to soluble factors produced by the tumor. Together, these data suggest that tumor burden may induce increased Treg infiltration, proliferation, and survival, negating productive anti-tumor immune responses in patients treated with immunotherapies. Collectively, our data indicate that several mechanisms of Treg recruitment and retention in the tumor microenvironment exist and may need to be addressed to improve the specificity of immunotherapies seeking to eliminate Treg in patients with glioma.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22406925      PMCID: PMC3337302          DOI: 10.1093/neuonc/nos014

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


  52 in total

1.  A comprehensive functional analysis of PTEN mutations: implications in tumor- and autism-related syndromes.

Authors:  Isabel Rodríguez-Escudero; María D Oliver; Amparo Andrés-Pons; María Molina; Víctor J Cid; Rafael Pulido
Journal:  Hum Mol Genet       Date:  2011-08-09       Impact factor: 6.150

2.  Chronic inflammation promotes myeloid-derived suppressor cell activation blocking antitumor immunity in transgenic mouse melanoma model.

Authors:  Christiane Meyer; Alexandra Sevko; Marcel Ramacher; Alexandr V Bazhin; Christine S Falk; Wolfram Osen; Ivan Borrello; Masashi Kato; Dirk Schadendorf; Michal Baniyash; Viktor Umansky
Journal:  Proc Natl Acad Sci U S A       Date:  2011-10-03       Impact factor: 11.205

3.  Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer.

Authors:  B Almand; J I Clark; E Nikitina; J van Beynen; N R English; S C Knight; D P Carbone; D I Gabrilovich
Journal:  J Immunol       Date:  2001-01-01       Impact factor: 5.422

4.  Tumor development after 3-methylcholanthrene in immunologically deficient athymic-nude mice.

Authors:  O Stutman
Journal:  Science       Date:  1974-02-08       Impact factor: 47.728

5.  Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors.

Authors:  A S Dighe; E Richards; L J Old; R D Schreiber
Journal:  Immunity       Date:  1994-09       Impact factor: 31.745

6.  Cancer immunotherapy: moving beyond current vaccines.

Authors:  Steven A Rosenberg; James C Yang; Nicholas P Restifo
Journal:  Nat Med       Date:  2004-09       Impact factor: 53.440

7.  Tissue factor in microvesicles shed from U87MG human glioblastoma cells induces coagulation, platelet aggregation, and thrombogenesis.

Authors:  E Bastida; A Ordinas; G Escolar; G A Jamieson
Journal:  Blood       Date:  1984-07       Impact factor: 22.113

8.  Normal adult ramified microglia separated from other central nervous system macrophages by flow cytometric sorting. Phenotypic differences defined and direct ex vivo antigen presentation to myelin basic protein-reactive CD4+ T cells compared.

Authors:  A L Ford; A L Goodsall; W F Hickey; J D Sedgwick
Journal:  J Immunol       Date:  1995-05-01       Impact factor: 5.422

Review 9.  The immunobiology of cancer immunosurveillance and immunoediting.

Authors:  Gavin P Dunn; Lloyd J Old; Robert D Schreiber
Journal:  Immunity       Date:  2004-08       Impact factor: 31.745

10.  PTEN, NHERF1 and PHLPP form a tumor suppressor network that is disabled in glioblastoma.

Authors:  J R Molina; N K Agarwal; F C Morales; Y Hayashi; K D Aldape; G Cote; M-M Georgescu
Journal:  Oncogene       Date:  2011-08-01       Impact factor: 9.867

View more
  64 in total

1.  More on the immune privilege of glioblastoma.

Authors:  Michael Weller
Journal:  Neuro Oncol       Date:  2012-05       Impact factor: 12.300

2.  Melanoma growth effects on molecular clearance from tumors and biodistribution into systemic tissues versus draining lymph nodes.

Authors:  Nathan Andrew Rohner; Susan Napier Thomas
Journal:  J Control Release       Date:  2015-12-23       Impact factor: 9.776

Review 3.  Combining immunotherapy with radiation for the treatment of glioblastoma.

Authors:  Kevin K H Chow; Wendy Hara; Michael Lim; Gordon Li
Journal:  J Neurooncol       Date:  2015-04-17       Impact factor: 4.130

Review 4.  Immunosuppressive mechanisms in glioblastoma.

Authors:  Edjah K Nduom; Michael Weller; Amy B Heimberger
Journal:  Neuro Oncol       Date:  2015-11       Impact factor: 12.300

Review 5.  Immunotherapy for neuro-oncology: the critical rationale for combinatorial therapy.

Authors:  David A Reardon; Mark R Gilbert; Wolfgang Wick; Linda Liau
Journal:  Neuro Oncol       Date:  2015-11       Impact factor: 12.300

Review 6.  Engineering challenges for brain tumor immunotherapy.

Authors:  Johnathan G Lyon; Nassir Mokarram; Tarun Saxena; Sheridan L Carroll; Ravi V Bellamkonda
Journal:  Adv Drug Deliv Rev       Date:  2017-06-15       Impact factor: 15.470

Review 7.  Microenvironmental clues for glioma immunotherapy.

Authors:  Michael Platten; Katharina Ochs; Dieter Lemke; Christiane Opitz; Wolfgang Wick
Journal:  Curr Neurol Neurosci Rep       Date:  2014-04       Impact factor: 5.081

Review 8.  T-cell Dysfunction in Glioblastoma: Applying a New Framework.

Authors:  Karolina I Woroniecka; Kristen E Rhodin; Pakawat Chongsathidkiet; Kristin A Keith; Peter E Fecci
Journal:  Clin Cancer Res       Date:  2018-03-28       Impact factor: 12.531

9.  The immune checkpoint protein PD-L1 induces and maintains regulatory T cells in glioblastoma.

Authors:  Joseph DiDomenico; Jonathan B Lamano; Daniel Oyon; Yuping Li; Dorina Veliceasa; Gurvinder Kaur; Leonel Ampie; Winward Choy; Jason B Lamano; Orin Bloch
Journal:  Oncoimmunology       Date:  2018-04-25       Impact factor: 8.110

10.  Gliomas promote immunosuppression through induction of B7-H1 expression in tumor-associated macrophages.

Authors:  Orin Bloch; Courtney A Crane; Rajwant Kaur; Michael Safaee; Martin J Rutkowski; Andrew T Parsa
Journal:  Clin Cancer Res       Date:  2013-04-23       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.